Kyntra Bio Inc KYNB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors
Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $3.57
- Day Range
- $3.60–3.82
- 52-Week Range
- $3.50–10.47
- Bid/Ask
- $3.61 / $3.74
- Shares Outstanding
- 4.05M
- Market Cap
- $14.90M
- Volume/Avg
- 19,322 / 24,281
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.13
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 34
- Website
- https://www.kyntrabio.com
Valuation
Metric | KYNB |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 3.13 |
Price/Cash Flow | 0.13 |
Price/Earnings
KYNB
Financial Strength
Metric | KYNB |
|---|---|
Quick Ratio | 2.54 |
Current Ratio | 2.69 |
Interest Coverage | −2.79 |
Quick Ratio
KYNB
Profitability
Metric | KYNB |
|---|---|
Return on Assets (Normalized) | −56.37% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
KYNB
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|#PW@$F | LOCK|^vB^ | $139B | |||
| Moderna Inc MRNA | LOCK|Bg$k>< | LOCK|st | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|>R?qkC | LOCK|G!WK | $95B | |||
| argenx SE ADR ARGX | LOCK|QG^H&z | LOCK|C!t | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|r>RtqX@ | LOCK|Tj | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|Mp^MV%>B | LOCK|!l^n | $31B | |||
| Incyte Corp INCY | LOCK|N#X&B^ | LOCK|%z% | $25B | |||
| BioNTech SE ADR BNTX | LOCK|D&%h!x | LOCK|XC | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|<$x$vn% | LOCK|>^pl | $20B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|nqL!NG | LOCK|?N$ | $16B |
United States